AVR
Anteris Technologies Global Corp.
NASDAQ · Healthcare · Medical - Devices · AU
$8.89
+1.95%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.1x
Market Cap
$866.41M
MomentumView details →
1D Return
+1.95%
YTD Return
+72.09%
RSI (14)
45.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.1x
Market Cap
$866.41M
RSI (14)
45.0
MomentumView details →
1D Return
+1.95%
YTD Return
+72.09%
SummaryUpdated Jun 1, 2026
Anteris Technologies Global Corp. (NASDAQ:AVR) is an Australian-based structural heart company that develops medical devices for treating aortic stenosis, a condition where the heart's aortic valve becomes narrowed and restricts blood flow. Founded in 1999 and headquartered in Toowong, Australia, the company went public on the NASDAQ in December 2024. Anteris focuses on creating innovative solutions for patients with heart valve disease, particularly through its transcatheter aortic valve replacement technology and proprietary anti-calcification tissue treatment.
Similar companies
Latest newsMore news →
Anteris Technologies Global Corp. reported its Q2 2026 financial results, with H1 2026 revenues of $1.503 million, up 28% year-over-year, and a net loss after tax of $51.675 million for H1 2026.24d agoL1 Capital Pty Ltd, a major shareholder of Anteris Technologies Global Corp., sold 174,721 shares of the company's stock on August 6, 2026, at an average price of $8.10, totaling $1,415,240.10.24d ago